Skip to main content
Have a personal or library account? Click to login
3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors Cover

3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors

Radiology and Oncology
Volume 45 (2011): Issue 3 (September 2011)
By:  and    
Open Access
|Jul 2011
References

References

  1. Buckner JC. Factors influencing survival in high-grade gliomas.2003;10-4.
    Open DOISearch in Google Scholar
  2. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.1993;704-10.
    Open DOISearch in Google Scholar
  3. Baur M, Preusser M, Piribauer M, Elandt K, Hassler M, Hudec M, et al. Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience.2010;113-20.
    Open DOISearch in Google Scholar
  4. Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S. A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999.2005;2798-806.
    Open DOISearch in Google Scholar
  5. Kachanov DY, Dobrenkov KV, Shamanskaya TV, Abdullaev RT, Inushkina EV, Savkova RF, et al. Solid tumors in young children in Moscow Region of Russian Federation.2008;39-44.
    Open DOISearch in Google Scholar
  6. Stupp R, Tonn JC, Brada M, Pentheroudakis G; ESMO Guidelines Working Group. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.2010;190-3.
    Open DOISearch in Google Scholar
  7. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.2002;1011-8.
    Open DOISearch in Google Scholar
  8. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of the for the treatment of brain tumours.2001;552-60.
    Open DOISearch in Google Scholar
  9. Stupp R, Hegi ME. Recent developments in the management of malignant glioma. In: Perry M, editor.. Alexandria, VA: American Society of Clinical Oncology; 2003. p. 779-88.
    Search in Google Scholar
  10. DeAngelis LM. Brain tumors.2001;114-23.
    Open DOISearch in Google Scholar
  11. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.2005;987-96.
    Open DOISearch in Google Scholar
  12. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.1993;704-10.
    Open DOISearch in Google Scholar
  13. Mahaley MS Jr, Mettlin C, Natarajan N, Laws ER Jr, Peace BB. National survey of patterns of care for brain-tumor patients.1989;826-36.
    Open DOISearch in Google Scholar
  14. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, et al. Changing paradigms - An update on the multidisciplinary management of malignant glioma.2006;165-80.
    Open DOISearch in Google Scholar
  15. Khasraw M, Bell D, Wheeler H. Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?2009,854-5.
    Open DOISearch in Google Scholar
  16. Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas.2010;26-33.
    Open DOISearch in Google Scholar
  17. Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Büyükberber S. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis.2009;191-7.
    Open DOISearch in Google Scholar
  18. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma.2005;997-1003.
    Open DOISearch in Google Scholar
  19. Velnar T, Smrdel U, Popovic M, Bunc G. Genetic markers in oligodendroglial tumours.2010;13-8.
    Open DOISearch in Google Scholar
  20. Komotar RJ, Otten ML, Moise G, Connolly, Jr. ES. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma - a critical review.2008:421-2.
    Open DOISearch in Google Scholar
  21. Gerstein J, Franz K, Steinbach JP, Seifert V, Fraunholz I, Weiss C, et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.2010;382-6.
    Open DOISearch in Google Scholar
  22. Walker MD, Strike TA, Sheline GE. An analysis of doseeffect relationship in the radiotherapy of malignant gliomas.1979;1725-31.
    Open DOISearch in Google Scholar
  23. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party.1991;769-74.
    Search in Google Scholar
  24. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORT C 26981/22981-NCIC CE3 phase - III randomized trial.2006;2563-9.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10019-011-0019-2 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 213 - 219
Published on: Jul 20, 2011
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
glioblastoma multiforme,
conformal radiotherapy,
temozolomide,
prognostic factors
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2011 Yilmaz Tezcan, Mehmet Koc, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 45 (2011): Issue 3 (September 2011)
Previous article
Next article